{"id":"W4402565567","doi":"10.1016/j.annonc.2024.08.2317","title":"LBA74 Final analysis of the phase III LITESPARK-005 study of belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"Merck Sharp and Dohme; EMD Serono; Genentech; Ipsen; European Association of Urology; European Society for Medical Oncology; Eisai; Astellas Pharma; Daiichi Sankyo Europe; Gilead Sciences; Calithera Biosciences; Jounce Therapeutics; Aptitude Health; Arrowhead Pharmaceuticals; Seagen; Society for Immunotherapy of Cancer; EUSA Pharma; Invitae; AstraZeneca; Associazione Italiana di Oncologia Medica; Pfizer; Incyte; F. Hoffmann-La Roche; Bristol-Myers Squibb; Eli Lilly and Company; American Society of Clinical Oncology; Exelixis; Sanofi; Amgen; Dana-Farber Cancer Institute","keywords":"Medicine; Everolimus; Renal cell carcinoma; Clear cell renal cell carcinoma; Oncology; Internal medicine; Urology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004370074,0.001299556,0.002878937,0.0005178467,0.0005632148,0.001955681,0.001216769,0.0009012561,0.007314655],"category_scores_gemma":[0.002957426,0.0008910829,0.004577576,0.0008060045,0.000718488,0.001225414,0.0005959461,0.002695217,0.001569157],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001972615,"about_ca_system_score_gemma":0.002658358,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004014337,"about_ca_topic_score_gemma":0.0144927,"domain_scores_codex":[0.9975478,0.001443663,0.0001041683,0.0003022405,0.000278206,0.0003239127],"domain_scores_gemma":[0.9987597,0.0003360158,0.0003012181,0.0001490633,0.0001353042,0.0003187547],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8956907,0.001342958,0.02519598,0.0007663056,0.02045087,0.0001532247,0.00008526646,0.002206021,0.006886048,0.0006449495,0.01374503,0.03283263],"study_design_scores_gemma":[0.6653862,0.07149926,0.197553,0.000252169,0.03242329,0.0003820089,0.0001823762,0.003427024,0.003407516,0.001602306,0.02372413,0.0001606195],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9585103,0.007591527,0.001618916,0.001375968,0.00045646,0.001416223,0.02087116,0.0003779123,0.007781404],"genre_scores_gemma":[0.965981,0.001074265,0.001747416,0.001366334,0.0002016566,0.001104044,0.02356779,0.0001335912,0.004823902],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007314655,"threshold_uncertainty_score":0.02446997,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1180007333120468,"score_gpt":0.3930948423803325,"score_spread":0.2750941090682856,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}